Literature DB >> 19147744

A systems approach to analysis of molecular complexity in breast cancer.

Bryan T Hennessy1, Ana Maria Gonzalez-Angulo, Mark S Carey, Gordon B Mills.   

Abstract

In this issue of Clinical Cancer Research, Andre et al. apply high-resolution arrays to elucidate copy number anomalies in breast cancer. They identify distinct copy number anomaly patterns in different breast cancer subtypes that implicate a number of genes as potential therapeutic targets and as potential markers of therapy responsiveness.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19147744      PMCID： PMC4161015          DOI： 10.1158/1078-0432.CCR-08-2620

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Authors:  Katrien Berns; Hugo M Horlings; Bryan T Hennessy; Mandy Madiredjo; E Marielle Hijmans; Karin Beelen; Sabine C Linn; Ana Maria Gonzalez-Angulo; Katherine Stemke-Hale; Michael Hauptmann; Roderick L Beijersbergen; Gordon B Mills; Marc J van de Vijver; René Bernards
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

2.  In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity.

Authors:  S Bautista; H Vallès; R L Walker; S Anzick; R Zeillinger; P Meltzer; C Theillet
Journal:  Clin Cancer Res       Date:  1998-12       Impact factor: 12.531

3.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.

Authors:  Anna Bergamaschi; Young H Kim; Pei Wang; Therese Sørlie; Tina Hernandez-Boussard; Per E Lonning; Robert Tibshirani; Anne-Lise Børresen-Dale; Jonathan R Pollack
Journal:  Genes Chromosomes Cancer       Date:  2006-11       Impact factor: 5.006

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

5.  The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.

Authors:  Kwai Wa Cheng; John P Lahad; Wen-Lin Kuo; Anna Lapuk; Kyosuke Yamada; Nelly Auersperg; Jinsong Liu; Karen Smith-McCune; Karen H Lu; David Fishman; Joe W Gray; Gordon B Mills
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

6.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

Authors:  Koei Chin; Sandy DeVries; Jane Fridlyand; Paul T Spellman; Ritu Roydasgupta; Wen-Lin Kuo; Anna Lapuk; Richard M Neve; Zuwei Qian; Tom Ryder; Fanqing Chen; Heidi Feiler; Taku Tokuyasu; Chris Kingsley; Shanaz Dairkee; Zhenhang Meng; Karen Chew; Daniel Pinkel; Ajay Jain; Britt Marie Ljung; Laura Esserman; Donna G Albertson; Frederic M Waldman; Joe W Gray
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

7.  Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers.

Authors:  Rebecca J Leary; Jimmy C Lin; Jordan Cummins; Simina Boca; Laura D Wood; D Williams Parsons; Siân Jones; Tobias Sjöblom; Ben-Ho Park; Ramon Parsons; Joseph Willis; Dawn Dawson; James K V Willson; Tatiana Nikolskaya; Yuri Nikolsky; Levy Kopelovich; Nick Papadopoulos; Len A Pennacchio; Tian-Li Wang; Sanford D Markowitz; Giovanni Parmigiani; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

8.  Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.

Authors:  J Bostner; M Ahnström Waltersson; T Fornander; L Skoog; B Nordenskjöld; O Stål
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

9.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.

Authors:  A Bellacosa; D de Feo; A K Godwin; D W Bell; J Q Cheng; D A Altomare; M Wan; L Dubeau; G Scambia; V Masciullo; G Ferrandina; P Benedetti Panici; S Mancuso; G Neri; J R Testa
Journal:  Int J Cancer       Date:  1995-08-22       Impact factor: 7.396

10.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962
View more
  4 in total

Review 1.  Future of personalized medicine in oncology: a systems biology approach.

Authors:  Ana Maria Gonzalez-Angulo; Bryan T J Hennessy; Gordon B Mills
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

2.  Translating cancer research into targeted therapeutics.

Authors:  J S de Bono; Alan Ashworth
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

3.  Site-specific activation of AKT protects cells from death induced by glucose deprivation.

Authors:  M Gao; J Liang; Y Lu; H Guo; P German; S Bai; E Jonasch; X Yang; G B Mills; Z Ding
Journal:  Oncogene       Date:  2013-02-11       Impact factor: 9.867

4.  Role of RPL39 in Metaplastic Breast Cancer.

Authors:  Bhuvanesh Dave; Daniel D Gonzalez; Zhi-Bin Liu; Xiaoxian Li; Helen Wong; Sergio Granados; Nadeer E Ezzedine; Douglas H Sieglaff; Joe E Ensor; Kathy D Miller; Milan Radovich; Agda KarinaEtrovic; Steven S Gross; Olivier Elemento; Gordon B Mills; Michael Z Gilcrease; Jenny C Chang
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.